indapamide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diuretics, sulfamoylbenzoic acid derivatives 1433 26807-65-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metindamide
  • indapamide hemihydrate
  • indapamide
  • flupamid
  • indaflex
  • indamide
  • indamol
  • veroxil
  • (+/-)-Indapamide
A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
  • Molecular weight: 365.83
  • Formula: C16H16ClN3O3S
  • CLOGP: 2.96
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 92.50
  • ALOGS: -4.03
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.59 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.20 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
July 6, 1983 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 1950.34 60.20 372 750 12953 2344010
Hypokalaemia 800.84 60.20 174 948 10480 2346483
Confusional state 492.20 60.20 139 983 24205 2332758
Acute kidney injury 410.86 60.20 125 997 27997 2328966
Fall 248.00 60.20 98 1024 47001 2309962
Inappropriate antidiuretic hormone secretion 235.41 60.20 49 1073 2260 2354703
Vomiting 196.02 60.20 94 1028 71508 2285455
Hypotension 171.68 60.20 68 1054 32368 2324595
Dehydration 150.94 60.20 56 1066 22239 2334724
Malaise 139.47 60.20 69 1053 55516 2301447
Conjoined twins 138.39 60.20 17 1105 11 2356952
Torsade de pointes 135.39 60.20 31 1091 2215 2354748
Hypomagnesaemia 126.08 60.20 30 1092 2534 2354429
Electrocardiogram QT prolonged 122.44 60.20 37 1085 7777 2349186
Dizziness 110.08 60.20 60 1062 58605 2298358
Hyponatraemic seizure 105.44 60.20 15 1107 60 2356903
Intestinal malrotation 102.30 60.20 14 1108 39 2356924
Urachal abnormality 98.78 60.20 12 1110 6 2356957
Persistent cloaca 95.84 60.20 12 1110 11 2356952
Blood sodium decreased 95.77 60.20 25 1097 3075 2353888
Left ventricular hypertrophy 95.39 60.20 19 1103 692 2356271
Drug interaction 93.51 60.20 43 1079 29120 2327843
Congenital bladder anomaly 93.48 60.20 12 1110 16 2356947
Syncope 87.50 60.20 35 1087 16840 2340123
Circulatory collapse 86.62 60.20 24 1098 3696 2353267
Renal impairment 81.63 60.20 29 1093 10063 2346900
Metabolic acidosis 79.45 60.20 25 1097 5973 2350990
Oedema peripheral 72.83 60.20 34 1088 23729 2333234
Hypertension 71.25 60.20 35 1087 27326 2329637
Dyslipidaemia 71.01 60.20 15 1107 732 2356231
Labile hypertension 65.70 60.20 10 1112 69 2356894
Hypertensive angiopathy 65.20 60.20 8 1114 5 2356958
Rhabdomyolysis 64.72 60.20 22 1100 6682 2350281
Orthostatic hypotension 64.36 60.20 18 1104 2861 2354102
Blood potassium decreased 61.54 60.20 20 1102 5285 2351678
Product packaging confusion 60.80 60.20 9 1113 50 2356913

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 587.35 52.65 130 538 8870 1737243
Hypokalaemia 309.51 52.65 73 595 6301 1739812
Acute kidney injury 250.04 52.65 90 578 34854 1711259
Hypotension 120.15 52.65 51 617 29603 1716510
Syncope 101.80 52.65 37 631 14132 1731981
Hyperkalaemia 95.13 52.65 31 637 8516 1737597
Hypertension 86.98 52.65 36 632 19412 1726701
Lactic acidosis 79.55 52.65 24 644 5105 1741008
Confusional state 77.28 52.65 34 634 21244 1724869
Seizure 75.31 52.65 33 635 20408 1725705
Drug interaction 71.40 52.65 35 633 27923 1718190
Dizziness 70.26 52.65 37 631 34324 1711789
Atrial fibrillation 67.52 52.65 28 640 15083 1731030
Hypomagnesaemia 65.50 52.65 17 651 2081 1744032
Arrhythmia 55.56 52.65 19 649 5997 1740116
Hypoosmolar state 55.24 52.65 7 661 8 1746105

Pharmacologic Action:

SourceCodeDescription
ATC C03BA11 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, EXCL. THIAZIDES
Sulfonamides, plain
ATC C09BX01 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors, other combinations
ATC C10BX13 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175420 Thiazide-like Diuretic
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004232 Diuretics
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35498 diuretic
MeSH PA D049993 Sodium Chloride Symporter Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Edema indication 267038008
Anuria contraindication 2472002 DOID:2983
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hyperparathyroidism contraindication 66999008 DOID:13543
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.53 acidic
pKa2 9.54 acidic
pKa3 5.52 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 12 member 3 Transporter INHIBITOR A2 7.54 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily KQT member 1 Ion channel WOMBAT-PK
Carbonic anhydrase 2 Enzyme Kd 6.70 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 8 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 6.67 CHEMBL
Carbonic anhydrase 13 Enzyme Kd 7 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.05 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 5.31 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 9.64 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.44 CHEMBL
Carbonic anhydrase 1 Enzyme Kd 5 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 6.56 CHEMBL
Carbonic anhydrase 6 Enzyme Kd 6.60 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.53 DRUG MATRIX
Carbonic anhydrase 13 Enzyme Ki 7.89 CHEMBL

External reference:

IDSource
D007190 MESH_DESCRIPTOR_UI
4018746 VUID
N0000147050 NUI
C0021186 UMLSCUI
D00345 KEGG_DRUG
74213004 SNOMEDCT_US
2360 MMSL
5764 RXNORM
387419003 SNOMEDCT_US
4873 MMSL
d00260 MMSL
4018746 VANDF
002313 NDDF
CHEMBL406 ChEMBL_ID
DB00808 DRUGBANK_ID
F089I0511L UNII
3333 INN_ID
180004-24-4 SECONDARY_CAS_RN
BL1 PDB_CHEM_ID
CHEBI:5893 CHEBI
3702 PUBCHEM_CID
7203 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 0228-2571 TABLET, FILM COATED 2.50 mg ORAL ANDA 12 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 0228-2597 TABLET, FILM COATED 1.25 mg ORAL ANDA 12 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 0378-0069 TABLET, FILM COATED 1.25 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 0378-0080 TABLET, FILM COATED 2.50 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 21695-576 TABLET, FILM COATED 1.25 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 42291-348 TABLET, FILM COATED 1.25 mg ORAL ANDA 12 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 42291-349 TABLET, FILM COATED 2.50 mg ORAL ANDA 12 sections
INDAPAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 43975-217 TABLET 1.25 mg ORAL ANDA 11 sections
INDAPAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 43975-304 TABLET 2.50 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 51079-868 TABLET, FILM COATED 2.50 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-024 TABLET, FILM COATED 1.25 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-025 TABLET, FILM COATED 2.50 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 62559-510 TABLET, FILM COATED 1.25 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 62559-511 TABLET, FILM COATED 2.50 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 63629-5216 TABLET, FILM COATED 2.50 mg ORAL ANDA 12 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 63629-7892 TABLET, FILM COATED 1.25 mg ORAL ANDA 12 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 68151-1294 TABLET, FILM COATED 1.25 mg ORAL ANDA 11 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 68788-7247 TABLET, FILM COATED 2.50 mg ORAL ANDA 12 sections
Indapamide HUMAN PRESCRIPTION DRUG LABEL 1 70518-1324 TABLET, FILM COATED 2.50 mg ORAL ANDA 12 sections